GLP weight-loss drug Ozempic has reportedly been linked to a rare form of vision loss, known as non-arteritic anterior ischemic optic neuropathy (NAION). The study, which has yet to be peer-reviewed, ...
Obesity dipped slightly in U.S. adults last year, research found — the first time in more than a decade that the country has ...
People taking Ozempic and Wegovy, which contain the drug semaglutide, may be at an increased risk of developing a ...
Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...
Brownstein and his team noted that women and adults aged 66 to 75 saw the largest decreases in obesity. People living in the ...
NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...
4h
Semaglutide use in diabetes patients is linked to a higher risk of NAION, a rare eye condition. A Danish-Norwegian study ...
Over half of American adults are eligible for semaglutide, but insurance and other barriers make it hard for people to access ...
Popular GLP-1 medications like semaglutide in Ozempic and Wegovy help people lose weight, but what should patients know about ...
It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...
Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in ...
Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online pharmacies say, in a sign the U.S. drugmaker is gaining ground on its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback